The investigational treatment inclisiran (The Medicines Company) was associated with a sustained reduction in low density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated doses of LDL-C lowering therapies.
Serum free fatty acid concentrations can distinguish children’s fed and fasting states.
According to the results of a recent study, the duration of antibiotic exposure in women during middle and older adulthood may significantly impact the risk of future cardiovascular (CVD) events. The study aimed to determine the association between both the duration of antibiotic exposure as well as the period of antibiotic use and subsequent…
Evidence supporting the clinical benefit of niacin monotherapy for secondary prevention of CVD appears to be outdated.
The FDA has approved the inclusion of new data from the ASCENT trial in the prescribing information for Tudorza Pressair.
Liraglutide and semaglutide demonstrated cardiorenal efficacy regardless of diabetes duration.
A systematic review compared the safety and efficacy of prasugrel and ticagrelor in patients with ACS undergoing PCI.
High-risk human papillomavirus infection may be associated with the risk for cardiovascular disease in Korean women.
No association seen for quality of plant-based diet and cancer-related deaths.
People receiving hormone therapy during gender transition have an increased risk for cardiovascular events.
